Atomo Diagnostics Ltd. (AU:AT1)
ASX:AT1
Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$16.24M
Enterprise ValueAU$16.17M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Capital StructureA very low debt-to-equity ratio (0.03) gives Atomo financial flexibility despite operational losses. Low leverage reduces insolvency risk and preserves capacity to fund R&D, product development or absorb near-term working capital shocks without immediate reliance on dilutive financing.
Proprietary RDT Platform And B2B ModelAtomo’s proprietary point-of-care and at-home RDT platform, integrated self-test formats, and B2B commercial model create durable competitive advantages. Licensing, design-for-manufacture, and contract supply relationships support recurring revenue potential and deeper industry partnerships over time.
Resilient Gross Margins At Product LevelA gross margin near 47% suggests the underlying product economics are reasonably healthy. If Atomo can stabilise volumes, this unit-level profitability provides a path to leverage fixed costs and improve operating margins, making recovery more achievable than with structurally weak unit economics.
Bears Say
Declining RevenueRevenue contraction of roughly 10% indicates weakening demand or contract timing issues. Continued top-line decline undermines scale, reduces bargaining power with partners and suppliers, and makes fixed-cost absorption harder, constraining margin recovery and long-term growth prospects.
Deep Operating Losses And Negative MarginsVery large negative EBIT and net margins show losses far exceed gross profits, signalling structural operating inefficiencies or high fixed costs. Persistent deep losses erode equity, limit reinvestment capacity, and increase the likelihood of external funding needs that can dilute shareholders.
Negative And Deteriorating Cash FlowNegative operating and falling free cash flow (-44% growth) point to deteriorating liquidity and operational cash generation. This raises runway risk, may force cost cuts or capital raises, and constrains investment in manufacturing scale or commercialization critical to long-term recovery.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$16.24M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 89 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Currently, no data Available
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AT1 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
-58.40%
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Technical Analysis
Options Prices
Currently, No data available
---